Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS Voorraadrapport

Marktkapitalisatie: US$30.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Marinus Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Marinus Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -15.5%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 9.4%. De inkomsten zijn groeide met een gemiddeld percentage van 47.6% per jaar.

Belangrijke informatie

-15.54%

Groei van de winst

16.43%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie5.95%
Inkomstengroei47.56%
Rendement op eigen vermogenn/a
Nettomarge-446.49%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Analyseartikel • Sep 20

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

It's not a stretch to say that Marinus Pharmaceuticals, Inc.'s ( NASDAQ:MRNS ) price-to-sales (or "P/S") ratio of 2.9x...
Analyseartikel • Aug 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest quarterly results, disappointing...
Analyseartikel • May 11

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) just released its latest first-quarter report and things are not looking...
Analyseartikel • Apr 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

The Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) share price has fared very poorly over the last month, falling by a...
Analyseartikel • Mar 08

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest annual results, disappointing...
Analyseartikel • Dec 22

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyseartikel • Sep 22

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Jun 12

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...
Analyseartikel • May 16

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Shareholders in Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) may be thrilled to learn that the analysts have just...
Analyseartikel • Oct 26

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

One thing we could say about the analysts on Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) - they aren't optimistic...
Analyseartikel • Oct 12

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Sep 22

Marinus Pharmaceuticals: Positive News Flow Of Note

Summary Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale of a priority review voucher and some additional cash flow from BARDA. An investment analysis follows in the paragraphs below. Humility means accepting reality with no attempt to outsmart it.”― David Richo When we last revisited Marinus Pharmaceuticals, Inc. (MRNS) in May, we recommended it for a small covered call position. That seems to have been a prudent call to this point as the stock is basically trading flat/slightly up to when we last looked at it. Given how poorly biotech stocks have traded in 2022, that marks a victory. Seeking Alpha We are circling back today to update the investment thesis around Marinus as the company has seen some positive news flow in recent weeks. An analysis follows below. Company Overview: Marinus Pharmaceuticals is focused on the development of therapies for the treatment of rare genetic epilepsies and other seizure disorders. The company is based outside of Philadelphia, PA. The stock trades for around $6.50 a share and sports an approximate market capitalization of $260 million. May Company Presentation The company has one primary asset under development for multiple indications called ganaxolone. This compound is also known by its brand name Ztalmy was approved this March for seizures associated with cyclin-dependent-kinase like 5 (CDKL5) deficiency disorder (CDD). The marketing application for Ztalmy in Europe is currently undergoing review by the European Medicines Agency or EMA. The company plans to submit complete responses to questions from the EMA in November and they should render a decision in the first quarter of next year. May Company Presentation Recent Developments for Marinus: The priority review voucher Marinus garnered via the approval of Ztalmy by the FDA was sold at the end of August for $110 million. This bolstered the company's cash reserves substantially and was right in the range ($100 million to $125 million) these vouchers have received in recent years. In addition, it was announced that Biomedical Advanced Research and Development Authority or BARDA had exercised its first contract option worth ~$12.3M, to support U.S. onshoring of manufacturing capabilities of Ztalmy. That still leaves some $39 million of potential awards under this contract, $21 million in previously approved base-period funding and up to $18 million across two additional option periods. Company Website The company continues to advance ganaxolone against other indications. Marinus has a Phase 3 trial "RAISE" to evaluate ganaxolone to treat Refractory Status Epilepticus or RSE. Topline results from this study should be out in the second half of 2023. This study is being funded by BARDA. May Company Presentation Recently the first patient was randomized and dosed in a Phase 3 trial to evaluate ganaxolone to treat Tuberous Sclerosis Complex or TSC. The study will consist of approximately targeting 80 clinical sites and topline results are not expected until the first quarter of 2024 at the earliest. May Company Presentation Results from a Phase 2 study around RSE was published in June and a Phase 3 study for RSE 'RAISE II' (for European registration) is expected to begin enrollment in the second half of 2023. May Company Presentation A Phase 2 trial 'RESET' evaluating ganaxolone in established status epilepticus on track to begin U.S. enrollment in the second half of this year. A Phase 2 trial to evaluate ganaloxone to treat Lennox-Gastaut syndrome is now targeted to begin in 2023. Analyst Commentary & Balance Sheet: The analyst community also seems to be turning more sanguine on Marinus' story. Over the past five weeks, four analyst firms including Robert W. Baird and JMP Securities have reissued Buy ratings on MRNS. Price targets proffered range from $17 to $32 a share. Approximately five percent of the outstanding float is currently held short. There has been no insider activity in this equity since March of 2021. The company ended the second quarter of this year with just over $90 million in cash and marketable securities on its balance sheet after posting a net loss of $39.4 million in the quarter. With the receipts from the priority review voucher in hand, management believes current funding levels are sufficient to fund it into the fourth quarter of 2023. Marinus has approximately $70 million of long term debt. Verdict: There are a wide range of sales and earnings estimates from the analyst community at the present time. Right now they expect the company to lose just over two bucks a share in FY2022 and over $3.50 a share in FY2023 as the company spends big on the rollout of Ztalmy and advancing its pipeline. Revenue estimates range from approximately $15 million to $60 million next fiscal year. The company had just $1.8 million worth of revenue in the second quarter.
Seeking Alpha • Aug 29

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Marinus Pharmaceuticals (NASDAQ:MRNS) on Monday said it had closed on the sale of a U.S. FDA voucher for $110M. The voucher, called the Rare Pediatric Disease Priority Review Voucher, entitles MRNS to a priority review from the agency and proceeds to carry out its drug development activities with an aim to treat rare pediatric diseases. MRNS said it had received the $110M of gross funds, which are in addition to the $92.3M the had reported in cash and cash equivalents as of June 30. The company said it would use the proceeds from the closing of the sale on the voucher for the commercial launch of seizure treatment Ztalmy, execution of its phase 3 clinical programs and other general expenditures. With the addition of this funding, MRNS said it now expects to fund its expenses and requirements and maintain the minimum cash balance required under its debt facility into Q4 2023. MRNS stock +4.2% to $6.97 after hours.
Analyseartikel • Aug 13

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Aug 10

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.93 (-43.1% Y/Y) and the consensus Revenue Estimate is $2.31M (+20.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Jul 28

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Marinus Pharmaceuticals (NASDAQ:MRNS) on Thursday announced the U.S. commercial launch of Ztalmy for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. CDD is a genetic disorder caused due to mutations in the CDKL5 gene. It is characterized by seizures, developmental delay and intellectual disability. Ztalmy, which is an oral treatment, got U.S. FDA approval earlier this year in March. Marinus (MRNS) also said it had established a patient support program called Ztalmy One which facilitates access to the treatment, including prescription benefits and financial support for patients with no insurance.
Seeking Alpha • May 05

Revisiting Marinus Pharmaceuticals

Today, we put biopharma concern Marinus Pharmaceuticals back in the spotlight for the first time in more than a year. Despite the fall in the stock recently, analyst firms remain strongly positive on the shares. An updated investment analysis follows in the paragraphs below.

Opbrengsten en kosten

Hoe Marinus Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:MRNS Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 2431-14063-12
30 Jun 2430-149660
31 Mar 2428-145650
31 Dec 2331-141610
30 Sep 2331-1346069
30 Jun 2326-29593
31 Mar 2322-35600
31 Dec 2225-20570
30 Sep 2220-14550
30 Jun 2228-105490
31 Mar 2228-91390
31 Dec 2115-99370
30 Sep 2115-88310
30 Jun 215-84280
31 Mar 214-76260
31 Dec 202-76190
30 Sep 200-7416-2
30 Jun 200-7214-18
31 Mar 200-6913-9
31 Dec 190-54120
30 Sep 190-491110
30 Jun 190-461136
31 Mar 190-43933
31 Dec 180-37928
30 Sep 180-31823
30 Jun 180-24817
31 Mar 180-19712
31 Dec 170-19712
30 Sep 170-20713
30 Jun 170-22715
31 Mar 170-27720
31 Dec 160-29722
30 Sep 160-30624
30 Jun 160-29622
31 Mar 160-25619
31 Dec 150-25619
30 Sep 150-21615
30 Jun 150-18513
31 Mar 150-17412
31 Dec 140-1339
30 Sep 140-1228
30 Jun 140-1227

Kwaliteitswinsten: MRNS is momenteel verliesgevend.

Groeiende winstmarge: MRNS is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: MRNS is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 15.5% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van MRNS over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: MRNS is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( -4.8% ).

Rendement op eigen vermogen

Hoge ROE: De schulden van MRNS zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2025/02/10 05:38
Aandelenkoers aan het einde van de dag2025/02/07 00:00
Inkomsten2024/09/30
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Marinus Pharmaceuticals, Inc. wordt gevolgd door 7 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Kimberly LeeBrean Capital Historical (Janney Montgomery)
François BriseboisCraig-Hallum Capital Group LLC
Douglas TsaoH.C. Wainwright & Co.